Roche Holding Ltd

Roche Posts Higher Sales on Growth Across Pharma, Diagnostics Units

Roche third quarter sales slightly beat expectations with growth across divisions

[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche setzt starke Dynamik im dritten Quartal mit Umsatzwachstum von +7% zu konstanten Wechselkursen (CER) und +8% in CHF fort; Konzernverkäufe steigen in den ersten neun Monaten 2026 um +6% (CER) […]

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […]

Roche says experimental MS pill cuts relapses by 55% in late-stage trials

Roche Partners With China's Hansoh in Deal That Could Top $15 Billion

Roche to unveil lung, breast cancer data at ESMO 2026

Roche Gets FDA Approval for Enspryng in Thyroid Eye Disease

4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month

Roche Expands Obesity Pipeline With Rona's RNAi Candidate

Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona Therapeutics

Roche Reports Positive Phase III Data on Eye Drug, FDA Accepts BLA

Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines

Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss

Gen Announces Appointment of Talbott Roche to Board of Directors

Roche Gets FDA Approval for Another Label Expansion of Tecentriq

FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer

BAYRY vs. RHHBY: Which Stock Should Value Investors Buy Now?

Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market?

Roche Holding AG (RHHBY) Discusses Pharma Strategy, R&D Excellence, AI in Drug Development, and Pipeline Updates Across Key Therapeutic Areas Transcript